Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting-Reference-Cited by-同舟云学术

Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting

Published:2023-07-07 Issue:1 Volume:12 Page:
ISSN:2162-3619
Container-title:Experimental Hematology & Oncology
language:en
Short-container-title:Exp Hematol Oncol

Author:

Chen Yiyin,Xu Yang,Wu Depei

Abstract

AbstractThis review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-thymocyte globulin, were discussed. The innovative agents and regimens highlighted in this review include abatacept, the first FDA-approved drug for acute GvHD prophylaxis; RGI-2001, which promotes the expansion of regulatory T cells; and cell therapies such as Orca-T and Orca-Q. These advancements provide promising strategies and options for GvHD prevention, offering hope for improved post-transplant patient outcomes in terms of survival rates.

Funder

the National Key R&D Program of China

the National Natural Science Foundation of China

Postgraduate Research & Practice Innovation Program of Jiangsu Province

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

https://link.springer.com/content/pdf/10.1186/s40164-023-00425-y.pdf

Reference12 articles.

1. Albanese A, Eran A, Suessmuth Y, Betz K, Bratrude B, Keskula P, et al. Early breakthrough T cell proliferation despite CNI/MTX prophylaxis is a harbinger of Acute GvHD (AGVHD) and is controlled by Abatacept: mechanism of success of the ABA2 AGvHD Prevention Trial. Blood. 2022 Nov;15(Supplement 1):274–5.

2. Kean LS, Burns LJ, Kou TD, Bond C, Kapikian R, Lozenski K et al. A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following Allogeneic Hematopoietic Cell Transplantation. Blood. 2022 Nov 15;140(Supplement 1):1373–5.

3. Raghunandan S, Gorfinkel L, Graiser M, Bratrude B, Betz K, Suessmuth Y, et al. Abatacept for the Prevention of GvHD in Pediatric and adult patients receiving 7/8 HLA-Mismatched unrelated transplant for hematologic malignancies: a real-world analysis. Blood. 2022 Nov;15(Supplement 1):7653–5.

4. Vorobyev VI, Subora AYu, Oleinik YA, Butaev LS, Zherebtsova VA, Kisilichina DG, et al. Abatacept/Tacrolimus or Abatacept/Tacrolimus/Post-Transplant cyclophosphamide are safe and highly effective in preventing graft-versus-host disease in matched or mismatched Donor Peripheral blood stem cell transplantation. Blood. 2022 Nov;15(Supplement 1):7622–3.

5. Chen YB, Saad A, Farhan SY, Lekakis LJ, Schiller GJ, Yared JA et al. RGI-2001 Infusion for Prevention of Acute GvHD after Allogeneic Hematopoietic Cell Transplantation. Blood. 2022 Nov 15;140(Supplement 1):1877–8.